Form 4: Cardiff Oncology Director James O. Armitage Acquires Stock Options
SEC Form 4 Filing
Director James O. Armitage acquired 29,700 stock options in Cardiff Oncology, Inc. on June 27, 2024.
Summary
- On June 27, 2024, James O. Armitage, a director of Cardiff Oncology, Inc., acquired 29,700 stock options.
- The exercise price of these options is $2.33.
- The options become exercisable on June 27, 2025, and expire on June 27, 2034.
- Following this transaction, Armitage directly owns 146,974 shares of Cardiff Oncology.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.
Positives
- A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to track the buying and selling activity of directors and officers, which can provide insights into their perspectives on the company's prospects.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment, as it may signal confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date of transaction: Acquisition of stock options. |
| 06/27/2025 | Date the stock options become exercisable. |
| 06/27/2034 | Expiration date of the stock options. |
| 07/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.